/MURA
MURA Stock - Mural Oncology plc
Healthcare|BiotechnologyNASDAQ
$2.04+0.00%
+$0.00 (+0.00%) • Dec 9
42
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.28
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.1
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.24
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MURA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.02 – $2.06
TARGET (TP)$2.35
STOP LOSS$1.88
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.96
52W High$4.74
52W Low$0.95
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A |
| Gross Profit | $-3,512,000 | $-2,567,000 | N/A | $-1,474,000 |
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Income | $-138,262,000 | $-194,638,000 | $-184,923,000 | $-175,365,000 |
| Net Income | $-128,514,000 | $-207,447,000 | $-189,807,000 | $-175,433,000 |
| Net Margin | N/A | N/A | N/A | N/A |
| EPS | $-7.58 | $-12.43 | $-11.37 | $-10.51 |
Company Overview
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
67%
Hold / Neutral
1
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish1 Neutral/Bearish
Price Targets
$15
Average Target
↑ 651.6% Upside
Now
$13
Low
$15
Average
$18
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 25th 2025 | Morgan Stanley | Downgrade | Equal Weight | - |
| March 25th 2025 | Raymond James | Downgrade | Outperform | $18 |
| June 28th 2024 | Rodman & Renshaw | Initiation | Buy | $15 |
| April 4th 2024 | Morgan Stanley | Initiation | Overweight | $13 |
Earnings History & Surprises
MURABeat Rate
71%
Last 7 quarters
Avg Surprise
+7.5%
EPS vs Estimate
Beats / Misses
5/2
Last 12 quarters
Latest EPS
$-0.21
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
+30.8%
$-1.84vs$-2.66
Q3 24
+2.1%
$-1.86vs$-1.90
Q4 24
+4.6%
$-1.87vs$-1.96
Q1 25
-1.5%
$-2.01vs$-1.98
Q2 25
+9.0%
$-1.93vs$-2.12
Q3 25
-56.6%
$-1.77vs$-1.13
Q4 25
+64.4%
$-0.21vs$-0.59
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 10, 2026 | $-0.37 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.59 | $-0.21 | +64.4% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | $-1.13 | $-1.77 | -56.6% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-2.12 | $-1.93 | +9.0% | ✓ BEAT |
Q1 2025 | Mar 11, 2025 | $-1.98 | $-2.01 | -1.5% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-1.96 | $-1.87 | +4.6% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-1.90 | $-1.86 | +2.1% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-2.66 | $-1.84 | +30.8% | ✓ BEAT |
Q1 2024 | Mar 26, 2024 | — | $-3.57 | — | — |
Q4 2023 | Dec 14, 2023 | — | $-3.07 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-3.13 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-2.78 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-3.52 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-3.03 | — | — |
Latest News
Mural Oncology Acquisition By XOMA Royalty Subsidiary Effective December 5, Under Companies Act Scheme
➖ NeutralBenzinga•Dec 5, 2025, 12:48 PM
Mural Oncology Shareholders To Receive $2.035 Per Share As XOMA Royalty Acquisition; Set To Close In Early December 2025
📈 PositiveBenzinga•Nov 26, 2025, 02:03 PM
Mural Oncology Shareholders Approve Takeover Of XOMA Royalty's XRA 5 Unit
📈 PositiveBenzinga•Oct 24, 2025, 08:27 PM
Reported Earlier, Mural Oncology Publishes Definitive Proxy Statement For XOMA Royalty Acquisition And Provides Scheme Meeting And EGM Details
➖ NeutralBenzinga•Sep 24, 2025, 06:35 AM
Mural Oncology shares are trading higher after the company announced it will be acquired by a Xoma Royalty subsidiary for between $2.035 and $2.24 cash per share.
📈 PositiveBenzinga•Aug 20, 2025, 05:38 PM
Mural Oncology To be Acquired By Xoma Royalty Subsidiary, XRA 5, For between $2.035 And $2.24 In Cash Per Share
📈 PositiveBenzinga•Aug 20, 2025, 12:31 PM
Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Aug 20, 2025, 12:25 PM
Frequently Asked Questions about MURA
What is MURA's current stock price?
Mural Oncology plc (MURA) is currently trading at $2.04 per share. The stock has moved +0.00% today.
What is the analyst price target for MURA?
No analyst price targets are currently available for this stock.
What sector is Mural Oncology plc in?
Mural Oncology plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MURA's market cap?
Mural Oncology plc has a market capitalization of $0.04 billion, making it a small-cap company.
Does MURA pay dividends?
No, Mural Oncology plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATHE
Alterity Therapeutics Limited
$3.09
Mkt Cap: $0.1B
BCAB
BioAtla, Inc.
$0.75
Mkt Cap: $0.0B
BTAI
BioXcel Therapeutics, Inc.
$1.73
Mkt Cap: $0.0B
EVAX
Evaxion Biotech A/S
$4.70
Mkt Cap: $0.0B
GBIO
Generation Bio Co.
$5.54
Mkt Cap: $0.0B
JSPR
Jasper Therapeutics, Inc.
$1.86
Mkt Cap: $0.0B
LIMN
Liminatus Pharma, Inc. Class A Common Stock
$0.79
Mkt Cap: $0.0B
SABS
SAB Biotherapeutics, Inc.
$3.99
Mkt Cap: $0.0B
VERU
Veru Inc.
$2.32
Mkt Cap: $0.0B
VRCA
Verrica Pharmaceuticals Inc.
$7.82
Mkt Cap: $0.1B
Explore stocks similar to MURA for comparison